Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials

The Lancet

Volumn 392, Issue 10152, 2018, Pages 1058-1070

  Meltzer Brody, Samantha ^a   Colquhoun, Helen ^b   Riesenberg, Robert ^c   Epperson, C Neill ^d   Deligiannidis, Kristina M ^e,f   Rubinow, David R ^a   Li, Haihong ^b   Sankoh, Abdul J ^b   Clemson, Christine ^b   Schacterle, Amy ^b   Jonas, Jeffrey ^b   Kanes, Stephen ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Sage Therapeutics Inc   (United States)

^c Atlanta Center for Medical Research   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Northwell Health   (United States)

^f ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREXANOLONE; PLACEBO; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BETA CYCLODEXTRIN DERIVATIVE; ELTANOLONE;

ADULT; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; POSTNATAL DEPRESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL IDEATION; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; PREGNANCY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; THIRD TRIMESTER PREGNANCY; YOUNG ADULT;

ADULT; BETA-CYCLODEXTRINS; DEPRESSION, POSTPARTUM; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GABA AGONISTS; HUMANS; INJECTIONS, INTRAVENOUS; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PREGNANOLONE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, GABA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85054775061     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31551-4     Document Type: Article

References (63)

1. Gavin, NI, Gaynes, BN, Lohr, KN, Meltzer-Brody, S, Gartlehner, G, Swinson, T, Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 106 (2005), 1071–1083.
2. Ko, JY, Rockhill, KM, Tong, VT, Morrow, B, Farr, SL, Trends in postpartum depressive symptoms-27 States, 2004, 2008, and 2012. MMWR Morb Mortal Wkly Rep 66 (2017), 153–158.
3. Howard, LM, Molyneaux, E, Dennis, CL, Rochat, T, Stein, A, Milgrom, J, Non-psychotic mental disorders in the perinatal period. Lancet 384 (2014), 1775–1788.
4. Earls, MF, Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics 126 (2010), 1032–1039.
5. Fellmeth, G, Fazel, M, Plugge, E, Migration and perinatal mental health in women from low- and middle-income countries: a systematic review and meta-analysis. BJOG 124 (2017), 742–752.
6. Postpartum Depression: Action Towards Causes and Treatment (PACT) Consotrium. Heterogeneity of postpartum depression: a latent class analysis. Lancet Psychiatry 2 (2015), 59–67.
7. Bauer, A, Parsonage, M, Knapp, M, Lemmi, V, Adelaja, B, The costs of perinatal mental health problems. 2014, London School of Economics, London https://www.nwcscnsenate.nhs.uk/files/3914/7030/1256/Costs_of_perinatal_mh.pdf. (Accessed 15 August 2018)
8. Chesney, E, Goodwin, GM, Fazel, S, Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 13 (2014), 153–160.
9. Johannsen, BM, Larsen, JT, Laursen, TM, Bergink, V, Meltzer-Brody, S, Munk-Olsen, T, All-cause mortality in women with severe postpartum psychiatric disorders. Am J Psychiatry 173 (2016), 635–642.
10. Parsons, CE, Young, KS, Rochat, TJ, Kringelbach, ML, Stein, A, Postnatal depression and its effects on child development: a review of evidence from low- and middle-income countries. Br Med Bull 101 (2012), 57–79.
11. Szegda, K, Markenson, G, Bertone-Johnson, ER, Chasan-Taber, L, Depression during pregnancy: a risk factor for adverse neonatal outcomes? A critical review of the literature. J Matern Fetal Neonatal Med 27 (2014), 960–967.
12. Accortt, EE, Cheadle, AC, Dunkel Schetter, C, Prenatal depression and adverse birth outcomes: an updated systematic review. Matern Child Health J 19 (2015), 1306–1337.
13. Field, T, Postpartum depression effects on early interactions, parenting, and safety practices: a review. Infant Behav Dev 33 (2010), 1–6.
14. Murray, L, Halligan, SL, Cooper, P, Effects of postnatal depression on mother-infant interactions, and child development. Bremner, JG, Wachs, TD, (eds.) Handbook of infant development, 2nd edn., 2010, Wiley-Blackwell, Malden, 192–220.
15. Netsi, E, Pearson, RM, Murray, L, Cooper, P, Craske, MG, Stein, A, Association of persistent and severe postnatal depression with child outcomes. JAMA Psychiatry 75 (2018), 247–253.
16. Muzik, M, Morelen, D, Hruschak, J, Rosenblum, KL, Bocknek, E, Beeghly, M, Psychopathology and parenting: an examination of perceived and observed parenting in mothers with depression and PTSD. J Affect Disord 207 (2017), 242–250.
17. Pearson, RM, Evans, J, Kounali, D, et al. Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry 70 (2013), 1312–1319.
18. Stein, A, Pearson, RM, Goodman, SH, et al. Effects of perinatal mental disorders on the fetus and child. Lancet 384 (2014), 1800–1819.
19. Goodman, SH, Broth, MR, Hall, CM, Stowe, ZN, Treatment of postpartum depression in mothers: Secondary benefits to the infants. Infant Ment Health J 29 (2008), 492–513.
20. NICE. Antenatal and postnatal mental health: clinical management and service guidance. https://www.nice.org.uk/guidance/cg192, 2014. (Accessed 15 August 2018)
21. O'Connor, E, Rossom, RC, Henninger, M, Groom, HC, Burda, BU, Primary care screening for and treatment of depression in pregnant and postpartum women: evidence report and systematic review for the US Preventive Services Task Force. JAMA 315 (2016), 388–406.
22. Siu, AL, Force, USPST, Bibbins-Domingo, K, et al. Screening for depression in adults: US Preventive Services Task Force Recommendation Statement. JAMA 315 (2016), 380–387.
23. Byatt, N, Biebel, K, Friedman, L, Debordes-Jackson, G, Ziedonis, D, Pbert, L, Patient's views on depression care in obstetric settings: how do they compare to the views of perinatal health care professionals?. Gen Hosp Psychiatry 35 (2013), 598–604.
24. Meltzer-Brody, S, Treating perinatal depression: risks and stigma. Obstet Gynecol 124 (2014), 653–654.
25. Di Florio, A, Putnam, K, Altemus, M, et al. The impact of education, country, race and ethnicity on the self-report of postpartum depression using the Edinburgh Postnatal Depression Scale. Psychol Med 47 (2017), 787–799.
26. Molyneaux, E, Howard, LM, McGeown, HR, Karia, AM, Trevillion, K, Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev, 9, 2014 CD002018.
27. Molyneaux, E, Telesia, LA, Henshaw, C, Boath, E, Bradley, E, Howard, LM, Antidepressants for preventing postnatal depression. Cochrane Database Syst Rev, 4, 2018 CD004363.
28. Cox, EQ, Sowa, NA, Meltzer-Brody, SE, Gaynes, BN, The perinatal depression treatment cascade: baby steps toward improving outcomes. J Clin Psychiatry 77 (2016), 1189–1200.
29. Melón, LC, Hooper, A, Yang, X, Moss, SJ, Maguire, J, Inability to suppress the stress-induced activation of the HPA axis during the peripartum period engenders deficits in postpartum behaviors in mice. Psychoneuroendocrinology 90 (2017), 182–193.
30. Maguire, J, Mody, I, GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron 59 (2008), 207–213.
31. Mody, I, Maguire, J, The reciprocal regulation of stress hormones and GABA(A) receptors. Front Cell Neurosci, 6, 2011, 4.
32. Meltzer-Brody, S, Howard, LM, Bergink, V, et al. Postpartum psychiatric disorders. Nat Rev Dis Primers, 4, 2018, 18022.
33. Majewska, MD, Harrison, NL, Schwartz, RD, Barker, JL, Paul, SM, Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232 (1986), 1004–1007.
34. Osborne, LM, Gispen, F, Sanyal, A, Yenokyan, G, Meilman, S, Payne, JL, Lower allopregnanolone during pregnancy predicts postpartum depression: an exploratory study. Psychoneuroendocrinology 79 (2017), 116–121.
35. Paul, SM, Purdy, RH, Neuroactive steroids. FASEB J 6 (1992), 2311–2322.
36. Luisi, S, Petraglia, F, Benedetto, C, et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab 85 (2000), 2429–2433.
37. Kanes, S, Colquhoun, H, Gunduz-Bruce, H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 390 (2017), 480–489.
38. First, MB, Spitzer, RL, Gibbon, M, Williams, JBW, Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV). 1996, American Psychiatric Press, Washington, DC.
39. Hamilton, M, A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960), 56–62.
40. Milgrom, J, Gemmill, AW, Bilszta, JL, et al. Antenatal risk factors for postnatal depression: a large prospective study. J Affect Disord 108 (2008), 147–157.
41. Serati, M, Redaelli, M, Buoli, M, Altamura, AC, Perinatal major depression biomarkers: a systematic review. J Affect Disord 193 (2016), 391–404.
42. Kanes, SJ, Colquhoun, H, Doherty, J, et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol, 32, 2017, e2576.
43. Guy, W, ECDEU assessment manual for psychopharmacology. 1976, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
44. Montgomery, SA, Asberg, M, A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979), 382–389.
45. Bech, P, Allerup, P, Gram, LF, et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 63 (1981), 290–299.
46. Gibbons, RD, Clark, DC, Kupfer, DJ, Exactly what does the Hamilton depression rating scale measure?. J Psychiatr Res 27 (1993), 259–273.
47. Pancheri, P, Picardi, A, Pasquini, M, Gaetano, P, Biondi, M, Psychopathological dimensions of depression: a factor study of the 17-item Hamilton depression rating scale in unipolar depressed outpatients. J Affect Disord 68 (2002), 41–47.
48. Maier, W, Philipp, M, Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 18 (1985), 114–115.
49. Cox, JL, Holden, JM, Sagovsky, R, Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 150 (1987), 782–786.
50. Spitzer, RL, Kroenke, K, Williams, JB, Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282 (1999), 1737–1744.
51. Spitzer, RL, Kroenke, K, Williams, JB, Lowe, B, A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166 (2006), 1092–1097.
52. Posner, K, Brown, GK, Stanley, B, et al. The Columbia-Suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168 (2011), 1266–1277.
53. Alexander, JL, Quest for timely detection and treatment of women with depression. J Manag Care Pharm 13:suppl 9A (2007), S3–S11.
54. Khan, A, Khan, SR, Shankles, EB, Polissar, NL, Relative sensitivity of the Montgomery-Asberg Depression rating scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol 17 (2002), 281–285.
55. Hantsoo, L, Ward-O'Brien, D, Czarkowski, KA, Gueorguieva, R, Price, LH, Epperson, CN, A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology 231 (2014), 939–948.
56. Kim, DR, Epperson, CN, Weiss, AR, Wisner, KL, Pharmacotherapy of postpartum depression: an update. Expert Opin Pharmacother 15 (2014), 1223–1234.
57. Wisner, KL, Hanusa, BH, Perel, JM, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol 26 (2006), 353–360.
58. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th edn., 2013, American Psychiatric Association, Washington, DC.
59. Flynn, HA, Davis, M, Marcus, SM, Cunningham, R, Blow, FC, Rates of maternal depression in pediatric emergency department and relationship to child service utilization. Gen Hosp Psychiatry 26 (2004), 316–322.
60. Kauppi, A, Kumpulainen, K, Vanamo, T, Merikanto, J, Karkola, K, Maternal depression and filicide-case study of ten mothers. Arch Womens Ment Health 11 (2008), 201–206.
61. Walsh, BT, Seidman, SN, Sysko, R, Gould, M, Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002), 1840–1847.
62. Khan, A, Fahl Mar, K, Faucett, J, Khan Schilling, S, Brown, WA, Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987–2013. World Psychiatry 16 (2017), 181–192.
63. Undurraga, J, Baldessarini, RJ, Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37 (2012), 851–864.